title: Effectiveness and tolerability of once versus twice daily nitrendipine in the treatment of mild to moderate hypertension. The Canadian Nitrendipine Study Group.
abstract: Improved measurement of plasma concentrations of nitrendipine demonstrates a plasma half-life of 17 to 21 h allowing once daily dosing for antihypertensive treatment. To determine the effectiveness and tolerability of nitrendipine given once versus twice daily, 78 patients with mild to moderate essential hypertension were randomized in a double-blind fashion to 12 weeks of treatment with either nitrendipine 20 mg once daily (n = 39) or nitrendipine 10 mg bid (n = 39). Blood pressures measured at the end of the dosing interval were similar on 20 mg once daily and 10 mg bid. Adverse events considered to be drug related (flushing and headaches) occurred mostly at the beginning of active treatment and more frequently on the once daily dosing, resulting in a greater number of patients being withdrawn from the once daily treatment group. Thus, nitrendipine 20 mg once daily lowered blood pressure as effectively as 10 mg bid but was associated with a higher incidence of adverse events. These could be minimized by starting at nitrendipine 10 mg once daily and increasing to 20 mg once daily after two to four weeks.
authors.affiliation: Health Sciences Centre, Winnipeg, Manitoba.
authors.forename: P
authors.initials: P
authors.lastname: Bolli
authors.forename: J
authors.initials: J
authors.lastname: Cobby
authors.forename: S P
authors.initials: SP
authors.lastname: Handa
authors.forename: L E
authors.initials: LE
authors.lastname: LaPlante
authors.forename: J
authors.initials: J
authors.lastname: Mukherjee
authors.forename: E Z
authors.initials: EZ
authors.lastname: Rabin
authors.forename: H A
authors.initials: HA
authors.lastname: Strong
authors.forename: J M
authors.initials: JM
authors.lastname: Wright
mesh_terms: D001794:Blood Pressure; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009568:Nitrendipine / Q000008:administration & dosage* / Q000009:adverse effects; D010349:Patient Compliance
chemical_list: D009568:Nitrendipine